UCL and Francis Crick-founded Achilles has raised series B funding at a reported $228m valuation and will now look to advance lung cancer and melanoma treatments.
Achilles Therapeutics, a UK-based cancer immunotherapy developer spun out from University College London and Francis Crick Institute, completed a £100m ($120m) series B round today led by fund manager RA Capital Management.
Life sciences investment trust Syncona also took part in the round, as did venture capital firm Forbion, hedge fund manager Perceptive Advisors, advisory firm Redmile Group and investment firm Invus. It valued the company at $228m according to the Financial Times.
Achilles is working on cancer…
